Show simple item record

dc.contributor.authorCetin, Arif Engin
dc.contributor.authorStevens, Mark M.
dc.contributor.authorCalistri, Nicholas L
dc.contributor.authorOlcum, Selim A.
dc.contributor.authorKimmerling, Robert John
dc.contributor.authorManalis, Scott R
dc.date.accessioned2017-11-28T20:49:38Z
dc.date.available2017-11-28T20:49:38Z
dc.date.issued2017-11
dc.date.submitted2017-08
dc.identifier.issn2041-1723
dc.identifier.urihttp://hdl.handle.net/1721.1/112320
dc.description.abstractMultiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse. Consequently, methods to select the most efficacious therapy are of great interest. Here we utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring their mass accumulation rate (MAR). We show that MAR accurately and rapidly defines therapeutic susceptibility across human multiple myeloma cell lines to a gamut of standard-of-care therapies. Finally, we demonstrate that our MAR assay, without the need for extended culture ex vivo, correctly defines the response of nine patients to standard-of-care drugs according to their clinical diagnoses. This data highlights the MAR assay in both research and clinical applications as a promising tool for predicting therapeutic response using clinical samples.en_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/s41467-017-01593-2en_US
dc.rightsCreative Commons Attribution 4.0 Internationalen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleDetermining therapeutic susceptibility in multiple myeloma by single-cell mass accumulationen_US
dc.typeArticleen_US
dc.identifier.citationCetin, Arif E. et al. “Determining Therapeutic Susceptibility in Multiple Myeloma by Single-Cell Mass Accumulation.” Nature Communications 8, 1 (November 2017): 1613 © 2017 The Author(s)en_US
dc.contributor.departmentDavid H. Koch Institute for Integrative Cancer Research at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Mechanical Engineeringen_US
dc.contributor.mitauthorCetin, Arif Engin
dc.contributor.mitauthorStevens, Mark M.
dc.contributor.mitauthorCalistri, Nicholas L
dc.contributor.mitauthorOlcum, Selim A.
dc.contributor.mitauthorKimmerling, Robert John
dc.contributor.mitauthorManalis, Scott R
dc.relation.journalNature Communicationsen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2017-11-28T20:09:57Z
dspace.orderedauthorsCetin, Arif E.; Stevens, Mark M.; Calistri, Nicholas L.; Fulciniti, Mariateresa; Olcum, Selim; Kimmerling, Robert J.; Munshi, Nikhil C.; Manalis, Scott R.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-3978-8478
dc.identifier.orcidhttps://orcid.org/0000-0002-5702-8667
dc.identifier.orcidhttps://orcid.org/0000-0002-6417-1007
dc.identifier.orcidhttps://orcid.org/0000-0001-9939-764X
dc.identifier.orcidhttps://orcid.org/0000-0001-5223-9433
mit.licensePUBLISHER_CCen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record